Skip to main content

Primary Aldosteronism

1
Pipeline Programs
7
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
CIN-107 2 mg dosingPhase 21 trial
Active Trials
NCT04605549Completed15Est. Oct 2024
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
CS-3150N/A2 trials
Active Trials
NCT02890173Completed1,001Est. Jul 2017
NCT02885662Completed44Est. Jul 2017
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
The oral sodium loading testN/A1 trial
Active Trials
NCT06750172Recruiting33Est. Dec 2024
Novartis
NovartisBASEL, Switzerland
1 program
captopril testN/A
Sandoz
SandozAustria - Kundl
1 program
captopril testN/A1 trial
Active Trials
NCT00917345Unknown150Est. May 2009
Autonomous Therapeutics
1 program
sequential combined AVSN/A1 trial
Active Trials
NCT07298954Recruiting456Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Daiichi SankyoCS-3150
AstraZenecaCIN-107 2 mg dosing
Autonomous Therapeuticssequential combined AVS
UNION therapeuticsThe oral sodium loading test
Daiichi SankyoCS-3150
Sandozcaptopril test

Clinical Trials (6)

Total enrollment: 1,699 patients across 6 trials

NCT02890173Daiichi SankyoCS-3150

Study of CS-3150 in Patients With Essential Hypertension

Start: Sep 2016Est. completion: Jul 20171,001 patients
Phase 3Completed
NCT04605549AstraZenecaCIN-107 2 mg dosing

A Study of CIN-107 in Adults With Primary Aldosteronism

Start: Mar 2021Est. completion: Oct 202415 patients
Phase 2Completed
NCT07298954Autonomous Therapeuticssequential combined AVS

Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE)

Start: Dec 2025Est. completion: Dec 2028456 patients
N/ARecruiting
NCT06750172UNION therapeuticsThe oral sodium loading test

Simplification of Oral Sodium Loading Test in the Diagnosis of Primary Aldosteronism: 2-day Replacing 3-day Method

Start: Dec 2023Est. completion: Dec 202433 patients
N/ARecruiting
NCT02885662Daiichi SankyoCS-3150

Study of CS-3150 in Patients With Primary Aldosteronism

Start: Sep 2016Est. completion: Jul 201744 patients
N/ACompleted
NCT00917345Sandozcaptopril test

Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity

Start: Jan 2008Est. completion: May 2009150 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,699 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.